Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1973 1
1974 3
1975 1
1976 9
1977 8
1978 5
1979 21
1980 14
1981 28
1982 44
1983 44
1984 36
1985 37
1986 42
1987 58
1988 32
1989 40
1990 55
1991 39
1992 37
1993 34
1994 20
1995 31
1996 18
1997 24
1998 34
1999 25
2000 30
2001 26
2002 37
2003 35
2004 34
2005 26
2006 30
2007 38
2008 23
2009 17
2010 35
2011 46
2012 47
2013 47
2014 38
2015 40
2016 26
2017 29
2018 30
2019 32
2020 25
2021 32
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

1,386 results
Results by year
Filters applied: . Clear all
Page 1
Oral Contraceptives in Dermatology.
Requena C, Llombart B. Requena C, et al. Actas Dermosifiliogr (Engl Ed). 2020 Jun;111(5):351-356. doi: 10.1016/j.ad.2019.06.006. Epub 2020 May 11. Actas Dermosifiliogr (Engl Ed). 2020. PMID: 32404240 Free article. Review. English, Spanish.
If we mainly consider a contraceptive's thrombotic profile when prescribing, the choice would be to have 30mug or less of ethinyl estradiol combined with levonorgestrel. On the other hand, if our main objective is to treat signs of androgenization, we would p …
If we mainly consider a contraceptive's thrombotic profile when prescribing, the choice would be to have 30mug or less of ethinyl
Hormonal contraception and breast cancer.
Westhoff CL, Pike MC. Westhoff CL, et al. Contraception. 2018 Sep;98(3):171-173. doi: 10.1016/j.contraception.2018.05.002. Contraception. 2018. PMID: 30193687 Free PMC article.
This study did not report on the risk associated with the use of a 20-mcg ethinyl estradiol pill. They did find an increasing risk in current users of longer duration and an increased risk with use of the levonorgestrel intrauterine system-both of these poten …
This study did not report on the risk associated with the use of a 20-mcg ethinyl estradiol pill. They did find an increasing …
Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics.
Adedoyin A, Cho CR, Fox-Bosetti S, Macha S, Zhao T, Liu F, Panebianco D, O'Reilly TE, McCrea J, Stoch SA, Iwamoto M. Adedoyin A, et al. Int J Clin Pharmacol Ther. 2019 Sep;57(9):450-457. doi: 10.5414/CP203483. Int J Clin Pharmacol Ther. 2019. PMID: 31232280
OBJECTIVE: Letermovir is an inhibitor of the terminase complex of cytomegalovirus (CMV) used as prophylactic therapy in CMV-seropositive allogeneic hematopoietic stem cell transplant recipients. As the combination oral contraceptive (COC) levonorgestrel/ethinyl e
OBJECTIVE: Letermovir is an inhibitor of the terminase complex of cytomegalovirus (CMV) used as prophylactic therapy in CMV-seropositive all …
Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.
Sriprasert I, Stanczyk FZ, Archer DF. Sriprasert I, et al. Expert Opin Pharmacother. 2015;16(12):1901-9. doi: 10.1517/14656566.2015.1056733. Expert Opin Pharmacother. 2015. PMID: 26194214
INTRODUCTION: The new transdermal contraceptive delivery system (TCDS) developed by Agile Therapeutics containing ethinyl estradiol and levonorgestrel (EE/LNG) is a reversible contraceptive method that maintains stable serum levels of both estrogen and proges …
INTRODUCTION: The new transdermal contraceptive delivery system (TCDS) developed by Agile Therapeutics containing ethinyl estradio
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
Nelson AL, Kaunitz AM, Kroll R, Simon JA, Poindexter AN, Castaño PM, Ackerman RT, Flood L, Chiodo JA 3rd, Garner EI; SECURE Investigators. Nelson AL, et al. Contraception. 2021 Mar;103(3):137-143. doi: 10.1016/j.contraception.2020.11.011. Epub 2020 Nov 28. Contraception. 2021. PMID: 33259782 Free article. Clinical Trial.
OBJECTIVE: To assess the contraceptive efficacy, safety, and tolerability of a contraceptive transdermal delivery system, (TDS; TWIRLA(R)) containing levonorgestrel (LNG) and ethinyl estradiol (EE). STUDY DESIGN: This single-arm, open-label, multicenter, 1-ye …
OBJECTIVE: To assess the contraceptive efficacy, safety, and tolerability of a contraceptive transdermal delivery system, (TDS; TWIRLA(R)) c …
Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.
Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM. Klipping C, et al. Contraception. 2021 Apr;103(4):213-221. doi: 10.1016/j.contraception.2021.01.001. Epub 2021 Jan 9. Contraception. 2021. PMID: 33428907 Free article. Clinical Trial.
Healthy subjects received either E4 15 mg/DRSP 3 mg (E4/DRSP) (n = 38), or ethinylestradiol (EE) 30 g/levonorgestrel (LNG) 150 g (n = 29), or EE 20 g/DRSP 3 mg (n = 31) for 6 treatment cycles. ...
Healthy subjects received either E4 15 mg/DRSP 3 mg (E4/DRSP) (n = 38), or ethinylestradiol (EE) 30 g/levonorgestrel (LNG) 150 g (n = …
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
Kaunitz AM, Portman D, Westhoff CL, Archer DF, Mishell DR Jr, Rubin A, Foegh M. Kaunitz AM, et al. Obstet Gynecol. 2014 Feb;123(2 Pt 1):295-303. doi: 10.1097/AOG.0000000000000095. Obstet Gynecol. 2014. PMID: 24402597 Clinical Trial.
OBJECTIVE: To compare a new low-dose levonorgestrel and ethinyl estradiol contraceptive patch (Patch) with a combination oral contraceptive (Pill; 100 micrograms levonorgestrel, 20 micrograms ethinyl estradiol) regarding efficacy, safety, …
OBJECTIVE: To compare a new low-dose levonorgestrel and ethinyl estradiol contraceptive patch (Patch) with a combinatio …
Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
Archer DF, Stanczyk FZ, Rubin A, Foegh M. Archer DF, et al. Contraception. 2012 Jun;85(6):595-601. doi: 10.1016/j.contraception.2011.10.006. Epub 2011 Nov 30. Contraception. 2012. PMID: 22133660 Clinical Trial.
BACKGROUND: This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15, a transdermal contraceptive delivery system, compared with a combination oral contraceptive (COC) containing EE 35 mcg and norgestimate …
BACKGROUND: This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200- …
1,386 results